I-Mab to Present at Jefferies Global Healthcare Conference

Rhea-AI Summary

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company specializing in precision immuno-oncology agents, has announced its participation in the Jefferies Global Healthcare Conference scheduled for June 3-5, 2025. The company's management will engage in a fireside chat and one-on-one meetings on June 5 at 3:45 PM ET.

Additionally, I-Mab revealed that new data regarding their lead program, givastomig, has been accepted for a Mini Oral presentation at the ESMO GI Cancers Congress 2025, taking place on July 2, 2025, in Barcelona, Spain.

News Market Reaction – IMAB

+0.30%

+0.30% Session move

In the trading session that priced this news, IMAB gained 0.30%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.

I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.

Conference details are as follows:

Jefferies Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Date: Thursday, June 5, 2025
Time: 3:45 PM ET
Webcast Link: Register here

About I-Mab

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.

I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com

FAQ

What will I-Mab (IMAB) present at the Jefferies Global Healthcare Conference 2025?

I-Mab's management will discuss clinical progress on their lead program, givastomig, during a fireside chat and one-on-one meetings on June 5, 2025, at 3:45 PM ET.

When and where will I-Mab present new givastomig data at ESMO GI 2025?

I-Mab will present new givastomig data in a Mini Oral presentation at the ESMO GI Cancers Congress 2025 on July 2, 2025, in Barcelona, Spain.

What is I-Mab's (IMAB) main focus as a company?

I-Mab is a U.S.-based, global biotech company focused on the development of precision immuno-oncology agents for the treatment of cancer.

What is givastomig and why is it important for I-Mab?

Givastomig is I-Mab's lead program in development, which will be discussed at both the Jefferies Healthcare Conference and ESMO GI Cancers Congress 2025.